250 related articles for article (PubMed ID: 18686044)
1. Current industrial practices in assessing CYP450 enzyme induction: preclinical and clinical.
Sinz M; Wallace G; Sahi J
AAPS J; 2008 Jun; 10(2):391-400. PubMed ID: 18686044
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of cynomolgus monkey pregnane X receptor, primary hepatocyte, and in vivo pharmacokinetic changes in predicting human CYP3A4 induction.
Kim S; Dinchuk JE; Anthony MN; Orcutt T; Zoeckler ME; Sauer MB; Mosure KW; Vuppugalla R; Grace JE; Simmermacher J; Dulac HA; Pizzano J; Sinz M
Drug Metab Dispos; 2010 Jan; 38(1):16-24. PubMed ID: 19833845
[TBL] [Abstract][Full Text] [Related]
3. The use of HepaRG and human hepatocyte data in predicting CYP induction drug-drug interactions via static equation and dynamic mechanistic modelling approaches.
Grime K; Ferguson DD; Riley RJ
Curr Drug Metab; 2010 Dec; 11(10):870-85. PubMed ID: 21208171
[TBL] [Abstract][Full Text] [Related]
4. Development of in vitro methods to predict induction of CYP1A2 and CYP3A4 in humans.
Grover GS; Brayman TG; Voorman RL; Ware JA
Assay Drug Dev Technol; 2007 Dec; 5(6):793-804. PubMed ID: 18052847
[TBL] [Abstract][Full Text] [Related]
5. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.
Singh SS
Curr Drug Metab; 2006 Feb; 7(2):165-82. PubMed ID: 16472106
[TBL] [Abstract][Full Text] [Related]
6. Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation.
LeCluyse EL
Eur J Pharm Sci; 2001 Jul; 13(4):343-68. PubMed ID: 11408150
[TBL] [Abstract][Full Text] [Related]
7. Environmental pollutants parathion, paraquat and bisphenol A show distinct effects towards nuclear receptors-mediated induction of xenobiotics-metabolizing cytochromes P450 in human hepatocytes.
Vrzal R; Zenata O; Doricakova A; Dvorak Z
Toxicol Lett; 2015 Oct; 238(1):43-53. PubMed ID: 26196221
[TBL] [Abstract][Full Text] [Related]
8. Induction of cytochrome P450 enzymes: a view on human in vivo findings.
Hukkanen J
Expert Rev Clin Pharmacol; 2012 Sep; 5(5):569-85. PubMed ID: 23121279
[TBL] [Abstract][Full Text] [Related]
9. Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery.
Yan Z; Caldwell GW
Curr Top Med Chem; 2001 Nov; 1(5):403-25. PubMed ID: 11899105
[TBL] [Abstract][Full Text] [Related]
10. Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes.
Prueksaritanont T; Richards KM; Qiu Y; Strong-Basalyga K; Miller A; Li C; Eisenhandler R; Carlini EJ
Pharm Res; 2005 Jan; 22(1):71-8. PubMed ID: 15771232
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of drug-drug interaction potential: present status of the application of primary human hepatocytes in the evaluation of cytochrome P450 induction.
Li AP; Maurel P; Gomez-Lechon MJ; Cheng LC; Jurima-Romet M
Chem Biol Interact; 1997 Nov; 107(1-2):5-16. PubMed ID: 9402946
[TBL] [Abstract][Full Text] [Related]
12. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes.
Luo G; Cunningham M; Kim S; Burn T; Lin J; Sinz M; Hamilton G; Rizzo C; Jolley S; Gilbert D; Downey A; Mudra D; Graham R; Carroll K; Xie J; Madan A; Parkinson A; Christ D; Selling B; LeCluyse E; Gan LS
Drug Metab Dispos; 2002 Jul; 30(7):795-804. PubMed ID: 12065438
[TBL] [Abstract][Full Text] [Related]
13. Nonylphenol-mediated CYP induction is PXR-dependent: The use of humanized mice and human hepatocytes suggests that hPXR is less sensitive than mouse PXR to nonylphenol treatment.
Mota LC; Barfield C; Hernandez JP; Baldwin WS
Toxicol Appl Pharmacol; 2011 May; 252(3):259-67. PubMed ID: 21376070
[TBL] [Abstract][Full Text] [Related]
14. In vitro assessment of P450 induction potential of novel chemopreventive agents SR13668, 9-cis-UAB30, and pentamethychromanol in primary cultures of human hepatocytes.
Jackson JP; Kabirov KK; Kapetanovic IM; Lyubimov A
Chem Biol Interact; 2009 May; 179(2-3):263-72. PubMed ID: 19135037
[TBL] [Abstract][Full Text] [Related]
15. Opportunities and challenges in using human hepatocytes in cytochromes P450 induction assays.
Dvorak Z
Expert Opin Drug Metab Toxicol; 2016; 12(2):169-74. PubMed ID: 26612411
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo induction of cytochrome p450: a survey of the current practices and recommendations: a pharmaceutical research and manufacturers of america perspective.
Chu V; Einolf HJ; Evers R; Kumar G; Moore D; Ripp S; Silva J; Sinha V; Sinz M; Skerjanec A
Drug Metab Dispos; 2009 Jul; 37(7):1339-54. PubMed ID: 19389860
[TBL] [Abstract][Full Text] [Related]
17. Semi-automatic quantitative RT-PCR to measure CYP induction by drugs in human hepatocytes.
Pérez G; Tabares B; Jover R; Gómez-Lechón MJ; Castell JV
Toxicol In Vitro; 2003; 17(5-6):643-9. PubMed ID: 14599457
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of human liver slices and reporter gene assays as systems for predicting the cytochrome p450 induction potential of drugs in vivo in humans.
Persson KP; Ekehed S; Otter C; Lutz ES; McPheat J; Masimirembwa CM; Andersson TB
Pharm Res; 2006 Jan; 23(1):56-69. PubMed ID: 16328606
[TBL] [Abstract][Full Text] [Related]
19. Effects of atorvastatin metabolites on induction of drug-metabolizing enzymes and membrane transporters through human pregnane X receptor.
Hoffart E; Ghebreghiorghis L; Nussler AK; Thasler WE; Weiss TS; Schwab M; Burk O
Br J Pharmacol; 2012 Mar; 165(5):1595-608. PubMed ID: 21913896
[TBL] [Abstract][Full Text] [Related]
20. Cell lines: a tool for in vitro drug metabolism studies.
Donato MT; Lahoz A; Castell JV; Gómez-Lechón MJ
Curr Drug Metab; 2008 Jan; 9(1):1-11. PubMed ID: 18220566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
